中国临床药理学与治疗学2024,Vol.29Issue(4) :415-422.DOI:10.12092/j.issn.1009-2501.2024.04.008

成人重度哮喘的免疫学特征和生物靶向治疗现状及展望

Immunologic characteristics and management and prospects of tar-geted biological therapy in adults with severe asthma

孙傲 王镜銮 刘文娟 任敦强 刘晓静
中国临床药理学与治疗学2024,Vol.29Issue(4) :415-422.DOI:10.12092/j.issn.1009-2501.2024.04.008

成人重度哮喘的免疫学特征和生物靶向治疗现状及展望

Immunologic characteristics and management and prospects of tar-geted biological therapy in adults with severe asthma

孙傲 1王镜銮 1刘文娟 2任敦强 1刘晓静1
扫码查看

作者信息

  • 1. 青岛大学附属医院呼吸与危重症医学科,青岛 266000,山东
  • 2. 青岛市黄岛区长江路街道社区卫生服务中心,青岛 266000,山东
  • 折叠

摘要

重度哮喘是哮喘患者致死和致残的主要因素,可造成巨大的社会和经济压力.近年来,随着对哮喘病理机制的深入了解,生物靶向治疗逐渐成为重度哮喘治疗的新选择.这些疗法通过精确抑制或调节炎症级联反应中的关键分子,从而有效缓解症状、改善肺功能,并降低急性发作的风险.它们标志着在重度哮喘治疗方面的范式转变.本文系统地探讨重度哮喘的免疫学特征,并对生物靶向治疗的现状和未来发展趋势进行全面评述,旨在为重度哮喘患者的个体化治疗提供科学、有益的参考依据.

Abstract

Severe asthma stands as a formidable contributor to both mortality and morbidity of pa-tients suffering asthma,casting substantial social and economic shadows on communities.As our un-derstanding of asthma's pathophysiology deepens,a beacon of hope emerges in the form of biological targeted therapies,offering a promising avenue for the management of this challenging condition.These therapies,by precisely inhibiting or modulat-ing pivotal molecules in the inflammatory cascade,offer potential benefits in symptom alleviation,lung function enhancement,and risk reduction of acute exacerbations.They signify a paradigm shift in severe asthma treatment.Within the confines of this article,we embark on a systematic exploration of the immunological underpinnings that define se-vere asthma.By delving into the intricacies of the immune system's role in exacerbating this condi-tion,we aim to offer a comprehensive assessment of both the current landscape and the future pros-pects of biological therapies.Our objective is to provide a scientifically robust and valuable refer-ence that can guide the individualized treatment of patients grappling with severe asthma.

关键词

重度哮喘/免疫学特征/生物靶向治疗

Key words

severe asthma/asthma phenotypes/biologics

引用本文复制引用

基金项目

国家自然科学基金青年基金(81300046)

青岛大学附属医院临床+X项目(3753)

青岛大学附属医院青年基金(3086)

出版年

2024
中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
参考文献量66
段落导航相关论文